Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technology Stocks & Market Talk With Don Wolanchuk -- Ignore unavailable to you. Want to Upgrade?

To: Winfastorlose who wrote (155615)	4/26/2021 11:27:39 PM
From: Winfastorlose	2 Recommendations Recommended By isopatch roguedolphin Read Replies (1) \| Respond to of 207068

Norwegian Institute of Public Health's recommendation about AstraZeneca vaccine Higher Risk associated with AstraZeneca vaccine than from COVID-19 disease in Norway Having come a long way in vaccinating the oldest citizens, Norway has reduced the risk of death for many of those most at risk. Since most of the elderly have either been vaccinated, or soon will be, this means that continued use of the vaccine would mainly be among the under-65 years age group if we were to use this vaccine in Norway. Calculations have been performed based on Norwegian data where the risk of dying from COVID-19 disease among the different age groups is compared with the risk of dying from the severe, but rare, condition with severe blood clots observed after AstraZeneca vaccination. "Since there are few people who die from COVID-19 in Norway, the risk of dying after vaccination with the AstraZeneca vaccine would be higher than the risk of dying from the disease, particularly for younger people," says Bukholm. In addition, there is reason to assume that there is scepticism about using the AstraZeneca vaccine in Norway, and it is uncertain how many people would have accepted an offer of this vaccine now.